Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Michael R Migden; Carola Berkin; Anne Lynn Chang; Et al.

doi:10.25251/skin.2.supp.77

Michael R Migden
Carola Berkin
Anne Lynn Chang
Et al.

Keywords

Abstract

Abstract not available.

Disclosures: Study sponsored by Regeneron Pharmaceuticals and Sanofi.

Poster PDF

Published

Dec 17, 2018

DOI https://doi.org/10.25251/skin.2.supp.77

How to Cite

Migden, M. R., Berkin, C., Chang, A. L., & al., E. (2018). Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, 2, S77. https://doi.org/10.25251/skin.2.supp.77

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas

Section

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Taofeek K Owonikoko, Kyriakos P Papadopoulos, Melissa L Johnson, Et al., Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
M Augustin, J Wegtowska, M Lebwohl, C Paul, V Piguet, H Sofen, A Blauvelt, L Peterson, Et al., Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
A Blauvelt, RB Warren, K Reich, et al., Durable Improvement in Patient Reported Outcomes across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
M Lebwohl, V Piguet, H Sofen, et al., The Efficacy of Certolizumab Pegol Re-Treatment on Plaque Psoriasis Following a Blinded Treatment Break: Results from the CIMPACT Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Martin Kaatz, Karl D Lewis, Nicole Basset-Seguin, Anne Lynn S Chang, Stéphane Dalle, Almudena Fernandez Orland, Lisa Licitra, Caroline Robert, Claas Ulrich, Axel Hauschild, Michael R Migden, Reinhard Dummer, Suk-Young Yoo, Ebony Coates, Emmanuel Okoye, Ioannis Bassukas, Carmen Loquai, Vincenzo De Giorgi, Zeynep Eroglu, Ralf Gutzmer, Jens Ulrich, Susana Puig, Frank Seebach, Israel Lowy, Matthew G Fury, Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Danny Rischin, Michael R Migden, Anne Lynn S Chang, Et al., Primary Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Metastatic Cutaneous Squamous Cell Carcinoma , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Paul Yamauchi, Chi-Chang Chen, Yao Ding, et al., Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Sarah J Kurley, Kyle R Covington, Kristen M Plasseraud, et al., Genes and biological functions governing intrinsic tumor biology utilized in cutaneous melanoma risk assessment through a clinically available 31-gene expression profile test , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)
Joshua A Zeichner, Julie C Harper, Wendy E Roberts, Et al., Novel Tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: Assessment of safety and tolerability in subgroups , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
Catherine Hren, Eduardo Tschen, Terry Jones, et al., Safety of Hydrogen Peroxide Topical Solution, 40% (w/w) in Patients With Skin of Color and Seborrheic Keratoses: Pooled Analysis of Two Phase 3, Randomized, Double- Blind, Vehicle-Controlled, Parallel-Group Studies , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 2 (2019)

<< < 1 2 3 > >>

Main Article Content

Keywords

Abstract

Article Sidebar

Article Details

Most read articles by the same author(s)